TY - JOUR
T1 - NTM drug discovery
T2 - status, gaps and the way forward
AU - Wu, Mu Lu
AU - Aziz, Dinah B.
AU - Dartois, Véronique
AU - Dick, Thomas
N1 - Funding Information:
We thank all participants of the workshop ‘Advancing Translational Science for Pulmonary NTM Infections’, organized by the National Institute of Allergy and Infectious Diseases and held in Rockville, MD, September 2017, for very stimulating and enlightening presentations and discussions. We also thank the anonymous reviewers for their useful and insightful comments. We are grateful to Pooja Gopal for her comments on the manuscript. We apologize to the many authors whose work could not be discussed and cited owing to space and reference limits. T.D. holds a Toh Chin Chye Visiting Professorship at the Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI132374 and by the Cystic Fibrosis Foundation under Award Number DICK17XX00 (to T.D.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Cystic Fibrosis Foundation.
Publisher Copyright:
© 2018 The Authors
PY - 2018/8
Y1 - 2018/8
N2 - Incidence of pulmonary diseases caused by non-tuberculous mycobacteria (NTM), relatives of Mycobacterium tuberculosis, is increasing at an alarming rate, surpassing tuberculosis in many countries. Current chemotherapies require long treatment times and the clinical outcomes are often disappointing. There is an urgent medical need to discover and develop new, more-efficacious anti-NTM drugs. In this review, we summarize the current status of NTM drug development, and highlight knowledge gaps and scientific obstacles in NTM drug discovery. We propose strategies to reduce biological uncertainties and to begin to populate a NTM drug pipeline with attractive leads and drug candidates. From crisis to cures – a review on status, knowledge gaps and major obstacles in NTM drug discovery and development, and how to move forward.
AB - Incidence of pulmonary diseases caused by non-tuberculous mycobacteria (NTM), relatives of Mycobacterium tuberculosis, is increasing at an alarming rate, surpassing tuberculosis in many countries. Current chemotherapies require long treatment times and the clinical outcomes are often disappointing. There is an urgent medical need to discover and develop new, more-efficacious anti-NTM drugs. In this review, we summarize the current status of NTM drug development, and highlight knowledge gaps and scientific obstacles in NTM drug discovery. We propose strategies to reduce biological uncertainties and to begin to populate a NTM drug pipeline with attractive leads and drug candidates. From crisis to cures – a review on status, knowledge gaps and major obstacles in NTM drug discovery and development, and how to move forward.
UR - http://www.scopus.com/inward/record.url?scp=85045574467&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045574467&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2018.04.001
DO - 10.1016/j.drudis.2018.04.001
M3 - Review article
C2 - 29635026
AN - SCOPUS:85045574467
SN - 1359-6446
VL - 23
SP - 1502
EP - 1519
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 8
ER -